LON:AVCT Avacta Group (AVCT) Share Forecast, Price & News GBX 129 +1.00 (+0.78%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range 126.25▼ 133.4550-Day Range 92▼ 13052-Week Range 87.99▼ 187.98Volume1.67 million shsAverage Volume1.54 million shsMarket Capitalization£360.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsHeadlinesProfileChartCompetitorsHeadlines About Avacta Group (LON:AVCT) StockAvacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.Read More AVCT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVCT Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comAvacta Group (LON:AVCT) Shares Pass Above 200-Day Moving Average of $112.48September 15, 2023 | americanbankingnews.comAvacta Group (LON:AVCT) Stock Passes Above Two Hundred Day Moving Average of $113.08September 24, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.September 11, 2023 | msn.comIf I’d invested £1,000 in Avacta shares 5 years ago, here’s how much I’d have nowAugust 11, 2023 | lse.co.ukAvacta Group Share ChatJune 21, 2023 | marketwatch.comAvacta Completes Fifth Dose Escalation in AVA6000 Phase 1 Clinical StudyJune 21, 2023 | finanznachrichten.deAvacta Group plc: Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical StudyJune 21, 2023 | finance.yahoo.comAvacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical StudySeptember 24, 2023 | The Oxford Club (Ad)He's Giving Away His Ultimate Dividend Package FOR FREE!Marc Lichtenfeld, Author of Get Rich with Dividends, is giving away his Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 8% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. For Free. June 19, 2023 | marketwatch.comAvacta Group Says No Fundraising Imminent; Shares RiseJune 6, 2023 | uk.finance.yahoo.comAVCT.L - Avacta Group PlcApril 27, 2023 | finance.yahoo.comFirst Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical StudyApril 5, 2023 | finanznachrichten.deAvacta Group plc: Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation StudyMarch 28, 2023 | finance.yahoo.comAvacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics DivisionMarch 16, 2023 | msn.comIs the Avacta share price dip a buying opportunity?January 17, 2023 | lse.co.ukBlock Listing Application to AIMOctober 21, 2022 | finance.yahoo.comAvacta Group Plc (LON:AVCT) is favoured by institutional owners who hold 58% of the companyOctober 1, 2022 | uk.finance.yahoo.comAvacta Group Plc (AVCT.L)September 5, 2022 | nasdaq.comAvacta's AVA6000 Gets FDA Orphan Drug Designation To Treat Soft Tissue Sarcoma; Stock UpJune 30, 2022 | finance.yahoo.comLG Chem Renews License Triggering Payment to AvactaMay 16, 2022 | benzinga.comAffyXell Expands its Strategic Partnership With...April 6, 2022 | proactiveinvestors.comAvacta full-year results push shares higherMarch 19, 2022 | finance.yahoo.comIs Avacta Group (LON:AVCT) In A Good Position To Invest In Growth?March 17, 2022 | uk.finance.yahoo.comWhat’s next for the Avacta share price?March 1, 2022 | uk.news.yahoo.comThe Avacta share price: buy or avoid like the plague?January 18, 2022 | msn.comAvacta Group selects second pre|CISION drug candidate for developmentJanuary 18, 2022 | finance.yahoo.comAvacta Selects Second pre|CISION™ Pro-drug Candidate for DevelopmentSee More Headlines Receive AVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter. Email Address AVCT Company Calendar Last Earnings9/28/2020Today9/24/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:AVCT CUSIPN/A CIKN/A Webwww.avacta.com Phone+44-1904-217070FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-39,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.55% Return on Assets-22.85% Debt Debt-to-Equity Ratio341.38 Current Ratio0.82 Quick Ratio4.96 Sales & Book Value Annual Sales£9.65 million Price / Sales37.34 Cash FlowGBX 8.60 per share Price / Cash Flow15.00 Book ValueGBX 7 per share Price / Book18.43Miscellaneous Outstanding Shares279,320,000Free FloatN/AMarket Cap£360.32 million OptionableNot Optionable Beta1.46 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. David Alastair Maclaughlin Smith (Age 57)CEO & Exec. Director Comp: $444kMr. Tony Gardiner (Age 52)CFO, Company Sec. & Exec. Director Comp: $273kMs. Emma WrightGroup In-House CounselMr. Michael VinegradGroup Communications DirectorMr. Craig Slater (Age 60)Chief Operating Officer of Diagnostics Dr. Matt JohnsonChief Scientific Officer of DiagnosticsDr. Neil Bell (Age 65)Chief Devel. Officer of Therapeutics Dr. Fiona McLaughlin FSB (Age 53)Ph.D., Chief Scientific Officer of Therapeutics Division Mr. David WilsonChief Commercial Officer of DiagnosticsMs. Karen HarrisonChief Operating Officer of Therapeutics DivisionMore ExecutivesKey CompetitorsHorizon Discovery Group plc (HZD.L)LON:HZDSilence TherapeuticsLON:SLNOxford BiomedicaLON:OXBVerona Pharma plc (VRP.L)LON:VRPFaron Pharmaceuticals OyLON:FARNView All Competitors AVCT Stock - Frequently Asked Questions How have AVCT shares performed in 2023? Avacta Group's stock was trading at GBX 115 at the beginning of 2023. Since then, AVCT shares have increased by 12.2% and is now trading at GBX 129. View the best growth stocks for 2023 here. How were Avacta Group's earnings last quarter? Avacta Group Plc (LON:AVCT) issued its quarterly earnings results on Monday, September, 28th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter. What other stocks do shareholders of Avacta Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avacta Group investors own include Legal & General Group (LGEN), SkinBioTherapeutics (SBTX), Augean (AUG), 7digital Group (7DIG), American Airlines Group (AAL), ACI Worldwide (ACIW), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Amyris (AMRS). What is Avacta Group's stock symbol? Avacta Group trades on the London Stock Exchange (LON) under the ticker symbol "AVCT." How do I buy shares of Avacta Group? Shares of AVCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Avacta Group's stock price today? One share of AVCT stock can currently be purchased for approximately GBX 129. How much money does Avacta Group make? Avacta Group (LON:AVCT) has a market capitalization of £360.32 million and generates £9.65 million in revenue each year. The biotechnology company earns £-39,540,000.00 in net income (profit) each year or GBX (0.14) on an earnings per share basis. How many employees does Avacta Group have? The company employs 120 workers across the globe. How can I contact Avacta Group? Avacta Group's mailing address is Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom. The official website for the company is www.avacta.com. The biotechnology company can be reached via phone at +44-1904-217070. This page (LON:AVCT) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.